As­traZeneca on 'in­de­pen­den­t' man­u­fac­tur­ing; Sam­sung Bio's next ADC deal

Wel­come to End­points News’ man­u­fac­tur­ing news briefs, where we bring you es­sen­tial up­dates on new builds, col­lab­o­ra­tions, re­calls and more.

As­traZeneca CEO Pas­cal So­ri­ot said dur­ing its fourth-quar­ter earn­ings press event that, al­though the phar­ma gi­ant does not source “a lot” of its prod­ucts with Catal­ent, the re­cent­ly-an­nounced No­vo-Catal­ent deal re­in­forces its aim to be as self-suf­fi­cient as pos­si­ble.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER